Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Выбор бета-блокатора для больных с метаболическим синдромом - Журнал Системные Гипертензии №1 (2008)
Выбор бета-блокатора для больных с метаболическим синдромом
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Cleophas Ton J. Experimental evidence of selective antagonistic action of Nebivolol on β1-adrenergic receptors. J Clin Med 1998; II: 1–8.
2. Van De Water A et al. Pharmacological and hemodynamic profile of Nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharm 1988; 11: 552–63.
3. Janssens WJ, Geyskens D, Proost F. Comparison of the β-adrenergic antagonistic effects of Nebivolol, carvedilol, celiprolol and bisoprolol on isolated right atria and trachea of the guinea-pig. Preclinical Research Report. June 1996.
4. Cockroft JR, Chowenczyk PHJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence of L-arginine/NO-dependent mechanism. J Pharmacol Exper Ther 1995; 274: 1067–71.
5. De Cree J et al. Double blind placebo-controlled cross-over study evaluating the acute haemodynamic effects of dl-Nebivolol 5 mg, d-Nebivolol 2,5 mg an l-Nebivolol 2,5 mg in healthy volunteers. JRF Clinical Research Report on R67555 NO-35. February 1989.
6. Blankestijn PJ et al. Nebivolol. An acute and long term study in essential hypertension. Drug Invest 1991; 3 (suppl. 1): 152–4.
7. Jennings G et al. Effects of Nebivolol on haemodynamics, cardiac dimensions and function, cardiovascular reflexes and biochemical measures of sympathetic activity in normal human subjects. Drug Invest. 1991; 3 (suppl. 1): 51–9.
8. Louis WJ et al. A study to establish the acute effects of Nebivolol on blood pressure and whether or not there are first dose postural effects in middle aged and elderly patients. Unpublished report on NEB-AUS-3, March 1995.
9. Van Rooy P et al. Phase I study: effects of Nebivolol 10 mg and 20 mg versus placebo on heart rate, blood pressure, systolic time intervals and side effects. A double-blind placebo-controlled cross-over study in healthy volunteers. JRF Clinical Research Report on R67555 NO-32. January 1989.
10. Zanchetti A. Trough: peak ratio of the blood pressure response to dihydropiridine calcium antagonists. J Hypertens 1994; 12 (8): S97–106.
11. Van Nueten L et al. Nebivolol versus nifedipine in treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Therapeutics 1998; 5: 237–43.
12. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2004.
2. Van De Water A et al. Pharmacological and hemodynamic profile of Nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharm 1988; 11: 552–63.
3. Janssens WJ, Geyskens D, Proost F. Comparison of the β-adrenergic antagonistic effects of Nebivolol, carvedilol, celiprolol and bisoprolol on isolated right atria and trachea of the guinea-pig. Preclinical Research Report. June 1996.
4. Cockroft JR, Chowenczyk PHJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence of L-arginine/NO-dependent mechanism. J Pharmacol Exper Ther 1995; 274: 1067–71.
5. De Cree J et al. Double blind placebo-controlled cross-over study evaluating the acute haemodynamic effects of dl-Nebivolol 5 mg, d-Nebivolol 2,5 mg an l-Nebivolol 2,5 mg in healthy volunteers. JRF Clinical Research Report on R67555 NO-35. February 1989.
6. Blankestijn PJ et al. Nebivolol. An acute and long term study in essential hypertension. Drug Invest 1991; 3 (suppl. 1): 152–4.
7. Jennings G et al. Effects of Nebivolol on haemodynamics, cardiac dimensions and function, cardiovascular reflexes and biochemical measures of sympathetic activity in normal human subjects. Drug Invest. 1991; 3 (suppl. 1): 51–9.
8. Louis WJ et al. A study to establish the acute effects of Nebivolol on blood pressure and whether or not there are first dose postural effects in middle aged and elderly patients. Unpublished report on NEB-AUS-3, March 1995.
9. Van Rooy P et al. Phase I study: effects of Nebivolol 10 mg and 20 mg versus placebo on heart rate, blood pressure, systolic time intervals and side effects. A double-blind placebo-controlled cross-over study in healthy volunteers. JRF Clinical Research Report on R67555 NO-32. January 1989.
10. Zanchetti A. Trough: peak ratio of the blood pressure response to dihydropiridine calcium antagonists. J Hypertens 1994; 12 (8): S97–106.
11. Van Nueten L et al. Nebivolol versus nifedipine in treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Therapeutics 1998; 5: 237–43.
12. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2004.
Авторы
В.Б.Мычка, Г.В.Рябыкина, Т.А.Шишова, В.П.Масенко, В.Б.Сергиенко, Г.Х.Шарипова, И.Е.Чазова
Отдел системных гипертензий Института клинической кардиологии им. А.Л.Мясникова, ФГУ Российский кардиологический научно-производственный комплекс МЗ и СР РФ, Москва
Отдел системных гипертензий Института клинической кардиологии им. А.Л.Мясникова, ФГУ Российский кардиологический научно-производственный комплекс МЗ и СР РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.